Commentary on LRAs targeting NF-κB with epigenetic and mutational impacts on HIV latency

关于靶向 NF-κB 的长效抗原靶向治疗 (LRAs) 对 HIV 潜伏期的表观遗传和突变影响的评论

阅读:2

Abstract

Human immunodeficiency virus (HIV) latency is controlled by factors like nuclear factor kappa B (NF-κB), which binds to the long terminal repeat of the HIV genome to start viral gene expression. The primary cellular form of NF-κB is a heterodimer comprising the DNA-binding subunit p50 and the transactivator p65. Phosphorylation of IkappaB kinase (IκB) is driven by the IκB kinase complex, whose core is formed by the NF-κB essential modulator. However, epigenetic changes like DNA methylation and histone modifications can suppress this activation. Recent studies show that HIV reservoirs are diverse, with complex interactions between viral and host factors affecting latency-reversing agent (LRA) effectiveness. Mutations in the NF-κB binding sites, converting them to GA-binding protein sites, complicate latency reversal by altering responses to LRAs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。